2025.08.212025.09.22 / CEO Ulrik Mouritzen joined Stephen Adams from Optimum Strategic Communications to discuss the successful completion of the Phase 1b study of orally administered hashtag#danegaptide, for the treatment ...

2025.06.252025.12.02 / Orally administered treatment was well tolerated, with early signs of clinical activity In models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against ...